BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 25422224)

  • 1. New formulated "DOX-MTX-loaded nanoparticles" down- regulate HER2 gene expression and improve the clinical outcome in OSCCs model in rat: the effect of IV and oral modalities.
    Abbasi MM; Monfaredan A; Hamishehkar H; Jahanban-Esfahlan R
    Asian Pac J Cancer Prev; 2014; 15(21):9355-60. PubMed ID: 25422224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel DOX-MTX nanoparticles improve oral SCC clinical outcome by down regulation of lymph dissemination factor VEGF-C expression in vivo: oral and IV modalities.
    Abbasi MM; Monfaredan A; Hamishehkar H; Seidi K; Jahanban- Esfahlan R
    Asian Pac J Cancer Prev; 2014; 15(15):6227-32. PubMed ID: 25124602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DOX-MTX-NPs augment p53 mRNA expression in OSCC model in rat: effects of IV and oral routes.
    Abbasi MM; Khiavi MM; Monfaredan A; Hamishehkar H; Seidi K; Jahanban-Esfahlan R
    Asian Pac J Cancer Prev; 2014; 15(19):8377-82. PubMed ID: 25339032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral and IV dosages of doxorubicin-methotrexate loaded- nanoparticles inhibit progression of oral cancer by down- regulation of matrix Methaloproteinase 2 expression in vivo.
    Abbasi MM; Jahanban-Esfahlan R; Monfaredan A; Seidi K; Hamishehkar H; Khiavi MM
    Asian Pac J Cancer Prev; 2014; 15(24):10705-11. PubMed ID: 25605162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of injectable doxorubicin & its nanodrug complex chemotherapy for the treatment of 4-nitroquinoline-1-oxide induced oral squamous cell carcinoma in rats.
    Khiavi MM; Abdal K; Abbasi MM; Hamishehkar H; Aghbali AA; Salehi R; Sina M; Abdollahi B; Fotohi S
    Indian J Med Res; 2017 Jan; 145(1):112-117. PubMed ID: 28574023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the Blood Parameters, Cardiac and Liver Enzymes in Oral Squamous Cell Carcinoma Following Treated with Injectable Doxorubicin-Loaded Nano-Particles.
    Moradzadeh Khiavi M; Anvari E; Hamishehkar H; Abdal K
    Asian Pac J Cancer Prev; 2019 Jul; 20(7):1973-1977. PubMed ID: 31350953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Codelivery of doxorubicin and MDR1-siRNA by mesoporous silica nanoparticles-polymerpolyethylenimine to improve oral squamous carcinoma treatment.
    Wang D; Xu X; Zhang K; Sun B; Wang L; Meng L; Liu Q; Zheng C; Yang B; Sun H
    Int J Nanomedicine; 2018; 13():187-198. PubMed ID: 29343957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hesa-A Down-Regulates erb/b2 Oncogene Expression and Improves Outcome of Oral Carcinoma in a Rat Model.
    Abbasi MM; Mehdipour M; Monfaredan A; Jahanban-Esfahlan R
    Asian Pac J Cancer Prev; 2015; 16(16):6947-51. PubMed ID: 26514473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance.
    Su L; Wang Y; Xiao M; Lin Y; Yu L
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Oct; 110(4):484-91. PubMed ID: 20868995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemosensitizing indomethacin-conjugated chitosan oligosaccharide nanoparticles for tumor-targeted drug delivery.
    Lee JY; Termsarasab U; Lee MY; Kim DH; Lee SY; Kim JS; Cho HJ; Kim DD
    Acta Biomater; 2017 Jul; 57():262-273. PubMed ID: 28483700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
    Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The activity against Ehrlich's ascites tumors of doxorubicin contained in self assembled, cell receptor targeted nanoparticle with simultaneous oral delivery of the green tea polyphenol epigallocatechin-3-gallate.
    Ray L; Kumar P; Gupta KC
    Biomaterials; 2013 Apr; 34(12):3064-76. PubMed ID: 23357370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of methotrexate and sequential methotrexate-5-fluorouracil for patients with recurrent squamous cell carcinoma of the oral cavity.
    Airoldi M; Pedani F; Brando V; Gabriele P; Orecchia R
    Chemioterapia; 1987 Dec; 6(6):390-2. PubMed ID: 3435920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Polyelectrolyte layer-by-layer assembled lipid nanoparticles for improving oral absorption of doxorubicin].
    Shen AJ; Xia DN; Gan Y; Li J
    Yao Xue Xue Bao; 2016 Jul; 51(7):1136-43. PubMed ID: 29897223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERBB2 gene amplification in oral squamous cell malignancies: a correlation with tumor progression and gene expression.
    Chu F; Feng Q; Qian Y; Zhang C; Fang Z; Shen G
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 Jul; 112(1):90-5. PubMed ID: 21531597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
    Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
    Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-invasion and anti-tumor growth effect of doxycycline treatment for human oral squamous-cell carcinoma--in vitro and in vivo studies.
    Shen LC; Chen YK; Lin LM; Shaw SY
    Oral Oncol; 2010 Mar; 46(3):178-84. PubMed ID: 20036604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance.
    Zhang D; Kong YY; Sun JH; Huo SJ; Zhou M; Gui YL; Mu X; Chen H; Yu SQ; Xu Q
    Int J Nanomedicine; 2017; 12():2081-2108. PubMed ID: 28356731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced chemotherapeutic efficacy of the low-dose doxorubicin in breast cancer via nanoparticle delivery system crosslinked hyaluronic acid.
    Wang Q; Zhong Y; Liu W; Wang Z; Gu L; Li X; Zheng J; Du H; Zhong Z; Xie F
    Drug Deliv; 2019 Dec; 26(1):12-22. PubMed ID: 30691317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Redox and pH-responsive gold nanoparticles as a new platform for simultaneous triple anti-cancer drugs targeting.
    Ghorbani M; Hamishehkar H
    Int J Pharm; 2017 Mar; 520(1-2):126-138. PubMed ID: 28167261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.